Halozyme Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Halozyme Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders online on April 25, 2024.</b>

AI Summary

HALOZYME THERAPEUTICS, INC. (HALO) filed a Proxy Statement (DEF 14A) with the SEC on March 15, 2024. The 2024 Annual Meeting of Stockholders for Halozyme Therapeutics, Inc. will be held online on April 25, 2024, at 12:00 p.m. Pacific Time. The filing is a Definitive Proxy Statement (DEF 14A) filed on March 15, 2024. The report covers the fiscal year ending December 31, 2023. The company's principal executive offices are located at 12390 El Camino Real, San Diego, CA 92130. The filing includes information on equity awards, options, and stock, distinguishing between PEO and Non-PEO members, and vested vs. unvested awards.

Why It Matters

For investors and stakeholders tracking HALOZYME THERAPEUTICS, INC., this filing contains several important signals. This DEF 14A filing provides stockholders with essential information regarding the upcoming annual meeting, including details about the agenda, voting procedures, and executive compensation, enabling informed participation. The detailed breakdown of equity awards and stock options is crucial for shareholders to understand potential dilution and the compensation structure for key personnel, impacting their investment decisions.

Risk Assessment

Risk Level: low — HALOZYME THERAPEUTICS, INC. shows low risk based on this filing. The filing is a routine proxy statement with no immediate financial or operational red flags, indicating a standard disclosure process.

Analyst Insight

Review the proxy statement for details on executive compensation, board nominations, and any shareholder proposals to make an informed voting decision.

Key Numbers

• 2024 — Annual Meeting Year (2024 Annual Meeting of Stockholders)
• April 25 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders)
• 12:00 p.m. Pacific Time — Annual Meeting Time (Time of the 2024 Annual Meeting of Stockholders)
• 2023 — Fiscal Year End (Conformed period of report)
• March 15, 2024 — Filing Date (Date the DEF 14A was filed)

Key Players & Entities

• HALOZYME THERAPEUTICS, INC. (company) — Registrant name
• 2024 Annual Meeting of Stockholders (event) — Meeting being announced
• April 25, 2024 (date) — Date of the annual meeting
• 12:00 p.m. Pacific Time (time) — Time of the annual meeting
• March 15, 2024 (date) — Filing date of the document
• 12390 El Camino Real, San Diego, CA 92130 (address) — Company's business and mailing address
• DEF 14A (document_type) — Filing type

FAQ

Key Dates

• 2024-04-25: 2024 Annual Meeting of Stockholders — Key date for stockholder participation and voting.
• 2024-03-15: DEF 14A Filing Date — Date the definitive proxy statement was filed with the SEC.
• 2023-12-31: Fiscal Year End — Period covered by the financial information in the proxy statement.

Filing Documents

• halo-20240313.htm (DEF 14A) — 920KB
• halo-20240313_g1.jpg (GRAPHIC) — 38KB
• halo-20240313_g10.jpg (GRAPHIC) — 27KB
• halo-20240313_g11.jpg (GRAPHIC) — 163KB
• halo-20240313_g12.jpg (GRAPHIC) — 135KB
• halo-20240313_g2.jpg (GRAPHIC) — 31KB
• halo-20240313_g3.jpg (GRAPHIC) — 16KB
• halo-20240313_g4.jpg (GRAPHIC) — 14KB
• halo-20240313_g5.jpg (GRAPHIC) — 36KB
• halo-20240313_g6.jpg (GRAPHIC) — 36KB
• halo-20240313_g7.jpg (GRAPHIC) — 51KB
• halo-20240313_g8.jpg (GRAPHIC) — 29KB
• halo-20240313_g9.jpg (GRAPHIC) — 27KB
• 0001159036-24-000024.txt (&nbsp;) — 2875KB
• halo-20240313.xsd (EX-101.SCH) — 4KB
• halo-20240313_def.xml (EX-101.DEF) — 5KB
• halo-20240313_lab.xml (EX-101.LAB) — 7KB
• halo-20240313_pre.xml (EX-101.PRE) — 4KB
• halo-20240313_htm.xml (XML) — 80KB

EXECUTIVE COMPENSATION AND RELATED INFORMATION

EXECUTIVE COMPENSATION AND RELATED INFORMATION 27 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 56

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 57 STOCKHOLDER PROPOSALS TO BE PRESENTED AT NEXT ANNUAL MEETING 59 TRANSACTION OF OTHER BUSINESS 59 DELIVERY OF PROXY MATERIALS AND ANNUAL REPORTS 60 HALOZYME THERAPEUTICS, INC. 12390 El Camino Real San Diego, California 92130 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held on April 25, 2024 TO THE STOCKHOLDERS OF HALOZYME THERAPEUTICS, INC.: Notice is hereby given that the Annual Meeting of the Stockholders of Halozyme Therapeutics, Inc., a Delaware corporation, will be held on April 25, 2024, at 12:00 p.m. Pacific Time. The meeting will be online only, so there is no physical meeting location. The Annual Meeting is being held for the following purposes: 1. To elect two Class II directors to hold office for a three-year term and until their respective successors are elected and qualified; 2. To approve, by a non-binding advisory vote, the compensation of our Named Executive Officers; 3. To approve an amendment to our Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers; 4. To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and 5. To transact such other business as may properly come before the Annual Meeting. You will be able to attend the Annual Meeting, submit questions and vote during the live webcast by visiting www.virtualshareholdermeeting.com/HALO2024 and entering the 16 digit control number included in your Notice of Internet Availability, on your proxy card, or voting instruction form, or in the instructions you received by email. Please refer to the additional logistical details and recommendations in the accompanying proxy statement. Only stockholders of record at the close of business on February 26, 2024 are entitled to notice of, and to vote at, this Annual Meeting and any a

: Gender Identity

Part I: Gender Identity Directors 5 3

: Demographic Background

Part II: Demographic Background African American or Black 0 0 Alaskan Native or Native American 0 0 Asian 2 0 Hispanic or Latinx 0 0 Native Hawaiian or Pacific Islander 0 0 White 3 3 Two or More Races or Ethnicities 0 0 To see our Board Diversity Matrix as of March 24, 2023, please see our proxy statement filed with the SEC on March 24, 2023. Directors Nominated for Election at the 2024 Annual Meeting Barbara Duncan (age 59) Director Since: 2023 Board Committees : Audit Committee and Compensation Committee Key Skills : Pharma Business Leadership and Operations, International Business, Finance and Capital Markets, M&A Other Current Public Company Boards : Atea Pharmaceuticals, Inc. Fusion Pharmaceuticals, Inc. Ovid Therapeutics, Inc. Recent Past Public Company Board Experience : Aevi Genomics Medicine, Inc., Adaptimmune Therapeutics, plc, Immunomedics, Inc., Innoviva, Inc., Jounce Therapeutics, Inc., ObsEva S.A. Ms. Duncan brings over 16 years of pharmaceutical and biotechnology industry experience to the Board of Directors. She retired from Intercept Pharmaceuticals, Inc., a biopharmaceutical company, where she served as Chief Financial Officer and Treasurer from May 2009 to June 2016. From 2001 to 2009, Ms. Duncan held various senior leadership roles of increasing responsibility at DOV Pharmaceutical, Inc., a biotechnology company, including Chief Financial Officer and ultimately serving as Chief Executive Officer prior to DOV's sale in 2010 to Euthymics Bioscience, Inc. Prior to joining DOV, Ms. Duncan served as Vice President of Corporate Finance-Global Healthcare at Lehman Brothers Inc. from 1998 to 2001, and as Director of Corporate Finance at SBC Warburg Dillon Read Inc. from 1994 to 1998. She also worked for PepsiCo, Inc. from 1989 to 1992 in its international audit division, and was a certified public accountant in the audit division of Deloitte & Touche LLP from 1986 to 1989. Ms. Duncan received her BBA from Louisi

View Full Filing

View this DEF 14A filing on SEC EDGAR